Sartorius AG (XTER:SRT) FFO


XTER:SRT Sartorius AG XTER:SRT
83 GF Score
Price €184.20
GF Value €202.80
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Sartorius AG FFO?

FFO (Funds from operations) only applies to REITs.

XTER:SRT
83GF Score
Sartorius AG XTER:SRT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius AG (XTER:SRT) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of €184.20 is trading 9.2% below its estimated GF Value™ of €202.80. GuruFocus considers Sartorius AG to be Fairly Valued.

Key valuation signals for XTER:SRT:

  • FFO:
  • GF Value™: €202.80 vs. price of €184.20 (9.2% below fair value)
  • GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the XTER:SRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
83GF Score

Get the complete analysis for XTER:SRT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€184.20
Price
€202.80
GF Value